Muzurovic, E, Haluzik, M, Horváth, L, Vlacho, B, Mauricio, D. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. CURRENT PHARMACEUTICAL DESIGN. 2026; 32(20)DOI:10.2174/0113816128378484250619080753. PMID:40641020. IF:2.800(Q2/5D).

Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).

Franch-Marti, C, Puig-Davi, A, Rodriguez-Antiguedad, J, Perez-Perez, J, Olmedo-Saura, G, Ruiz-Barrio, I, Bojtos, L, Perez-Carasol, L, Tort-Merino, A, Pagonabarraga, J, Kulisevsky, J, Martinez-Horta, S. Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease. Brain Communications. 2026; 8(3)DOI:10.1093/braincomms/fcag210. PMID:42339152. IF:(Q/D).

Ellebaek, E, Weichenthal, M, Gavrilova, I, Asher, N, Terheyden, P, Utikal, J, Suljeviic, AJ, Pföhler, C, Stojkovski, I, Herbst, RA, Ugurel, S, Ruhlmann, C, Berrocal, A, Majem, M, Dujovic, B, Sabaric, V, Duvancic, T, Soria, A, Donia, M, Schmidt, H, Friis, RB, Gerasimov, A, Shalamanova-Deleva, G, Kontilev, A, Lev-Ari, S, Shapira, R, Piccin, L, Minisini, A, Özdemir, BC, Teterycz, P, Mariuk-Jarema, A, Ziogas, D, Anastasopoulou, A, Stefanou, D, Gutiérrez, L, Gebhardt, C, Dummer, R, Hauschild, A, Mohr, P, von Wasielewski, I, Meier, F, Haanen, J, Svane, IM, Ascierto, PA, Mangana, J, Rutkowski, P, Gogas, H, Bastholt, L, Schadendorf, D. Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study. Ejc Skin Cancer. 2026; 4DOI:10.1016/j.ejcskn.2025.100773. PMID:. IF:(Q/D).